PRNB Principia Biopharma Inc.

31.08
-0.12  -0%
Previous Close 31.2
Open 31.45
Price To Book 6.67
Market Cap 1,019,007,839
Shares 32,786,610
Volume 186,239
Short Ratio
Av. Daily Volume 252,918
Stock charts supplied by TradingView

NewsSee all news

  1. Principia to Present at the Stifel Healthcare Conference 2019

    SOUTH SAN FRANCISCO, Calif., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (NASDAQ:PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today

  2. Principia Announces Proposed Public Offering of Common Stock

    SOUTH SAN FRANCISCO, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (NASDAQ:PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today

  3. Principia Announces Positive Preliminary Data of PRN1008 for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial

    SOUTH SAN FRANCISCO, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (NASDAQ:PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today announced

  4. Principia Announces Positive Preliminary Data of PRN1008 from its Ongoing Phase 2 Part B Trial in Pemphigus

    Consistent efficacy and safety profile for pemphigus patients observed  Confirms 400mg twice daily dose in Phase 3 trial Principia to host investor conference call at 8:00 am Eastern time SOUTH SAN FRANCISCO, Calif.,

  5. Principia Biopharma Appoints Shawn Tomasello to Its Board of Directors

    SOUTH SAN FRANCISCO, Calif., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (NASDAQ:PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due 1H 2022.
PRN1008 - PEGASUS
Pemphigus
Phase 2 data due at ASH December 2019.
PRN1008
Immune thrombocytopenic purpura (ITP)
Phase 2 data due 1Q 2020.
SAR442168 (PRN2246)
Multiple sclerosis
Phase 1 dose escalation data released May 20, 2019. Stable disease in 11/ 36 patients.
PRN1371
Urothelial Carcinoma
Phase 2 preliminary data released October 10, 2019 noted 6/15 patients have reached a complete response. Further update due later in 4Q 2019.
PRN1008
Pemphigus

Latest News

  1. Principia to Present at the Stifel Healthcare Conference 2019

    SOUTH SAN FRANCISCO, Calif., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (NASDAQ:PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today

  2. Principia Announces Proposed Public Offering of Common Stock

    SOUTH SAN FRANCISCO, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (NASDAQ:PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today

  3. Principia Announces Positive Preliminary Data of PRN1008 for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial

    SOUTH SAN FRANCISCO, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (NASDAQ:PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today announced

  4. Principia Announces Positive Preliminary Data of PRN1008 from its Ongoing Phase 2 Part B Trial in Pemphigus

    Consistent efficacy and safety profile for pemphigus patients observed  Confirms 400mg twice daily dose in Phase 3 trial Principia to host investor conference call at 8:00 am Eastern time SOUTH SAN FRANCISCO, Calif.,

  5. Principia Biopharma Appoints Shawn Tomasello to Its Board of Directors

    SOUTH SAN FRANCISCO, Calif., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (NASDAQ:PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with

  6. Principia to Present at the 2019 Baird Global Healthcare Conference and the Wells Fargo Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (NASDAQ:PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with